Lv7
5000 积分 2023-07-31 加入
Exposure–response analysis for selection of optimal dosage regimen of anifrolumab in patients with systemic lupus erythematosus
1个月前
已完结
Optimizing Early Clinical Investigations in Cancer Immunotherapy: The Translational Journey of RG6292, a Novel, Selective Treg‐Depleting Antibody
1个月前
已完结
Pharmacokinetic drug evaluation of daclizumab for the treatment of relapsing-remitting multiple sclerosis
1个月前
已完结
Human IgG subclass cross-species reactivity to mouse and cynomolgus monkey Fcγ receptors
2个月前
已完结
Use of pharmacokinetic versus pharmacodynamic endpoints to support human dose predictions: implications for rational drug design and early clinical development
2个月前
已完结
The preclinical discovery and development of secukinumab for the treatment of moderate-to-severe hidradenitis suppurativa
2个月前
已完结
A Quantitative Prediction Method for the Human Pharmacokinetics of Fc-Fusion Proteins
3个月前
已完结
Clinical Pharmacology Insights for Small Molecule and Antibody‐Based Drug Products Approved for Multiple Immune‐Mediated Indications
3个月前
已完结
Tu1453 A PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF P40XTL1A BISPECIFIC ANTIBODY PF-07261271 IN HEALTHY PARTICIPANTS
3个月前
已关闭
Assessing the clinical progress of the bispecific nanobody sonelokimab
5个月前
已完结
皖公网安备34019202002308
